It has finally begun! (Unity’s first treatment is in a human body)

First UNITY Clinical Trial Designed to Eliminate Senescent Cells Associated with Age-Related Diseases SAN FRANCISCO , June 25, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (?UNITY?) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or

http://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-inc-announces-first-patient-treated-ubx0101

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website, NutritionTheory.org

View all posts by Robert Zinn →